INTRODUCTION: Glucagon-like peptide 1 (GLP-1) is released in response to food intake and plays an important role in maintaining blood glucose homeostasis. Exendin (9-39), a potent glucagon-like peptide 1 receptor antagonist, has been labeled with In-111 for SPECT imaging. We report here the first radiosynthesis of [(18)F]exendin (9-39) ([(18)F]Ex(9-39)) and an evaluation of its potential as a biomarker for in vivo positron emission tomography (PET) imaging of pancreatic β-cell mass (BCM) in rats. METHODS: F-18 label was introduced by conjugation of [(18)F]4-fluorobenzaldehyde with an Ex(9-39) derivative containing a 6-hydrazinonicotinyl group on the ε-amine of Lys27. Positron emission tomography imaging was carried out in Sprague-Dawley rats (five control and five streptozotocin-induced diabetic) and BioBreeding diabetes-prone rats (three at 7 weeks and three at 12 weeks) using the high-resolution research tomograph (HRRT) after 0.187 ± 0.084 mCi [(18)F]Ex(9-39) administration. Time-activity curves were obtained from pancreas, liver and kidney. Pancreases were assayed for insulin content after the imaging study. RESULTS: Site-specifically labeled [(18)F]Ex(9-39) was purified on a G15 open column with radiochemical and chemical purities >98%. Positron emission tomography imaging showed pancreatic standardized uptake value (SUV) peaked at 10 min and plateaued by 50 min to the end of scan (240 min). No correlations of pancreatic SUV with postmortem measures of insulin content were seen. CONCLUSIONS: [(18)F]Ex(9-39) was successfully prepared and used for PET imaging for the first time to measure pancreatic BCM. The results suggest that derivatization of the Lys27 residue might reduce binding affinity, as evidenced by the absence of specific binding. Exendin analogues radiolabeled at other sites may elucidate the active site required for binding.
INTRODUCTION:Glucagon-like peptide 1 (GLP-1) is released in response to food intake and plays an important role in maintaining blood glucose homeostasis. Exendin (9-39), a potent glucagon-like peptide 1 receptor antagonist, has been labeled with In-111 for SPECT imaging. We report here the first radiosynthesis of [(18)F]exendin (9-39) ([(18)F]Ex(9-39)) and an evaluation of its potential as a biomarker for in vivo positron emission tomography (PET) imaging of pancreatic β-cell mass (BCM) in rats. METHODS:F-18 label was introduced by conjugation of [(18)F]4-fluorobenzaldehyde with an Ex(9-39) derivative containing a 6-hydrazinonicotinyl group on the ε-amine of Lys27. Positron emission tomography imaging was carried out in Sprague-Dawley rats (five control and five streptozotocin-induced diabetic) and BioBreeding diabetes-prone rats (three at 7 weeks and three at 12 weeks) using the high-resolution research tomograph (HRRT) after 0.187 ± 0.084 mCi [(18)F]Ex(9-39) administration. Time-activity curves were obtained from pancreas, liver and kidney. Pancreases were assayed for insulin content after the imaging study. RESULTS: Site-specifically labeled [(18)F]Ex(9-39) was purified on a G15 open column with radiochemical and chemical purities >98%. Positron emission tomography imaging showed pancreatic standardized uptake value (SUV) peaked at 10 min and plateaued by 50 min to the end of scan (240 min). No correlations of pancreatic SUV with postmortem measures of insulin content were seen. CONCLUSIONS: [(18)F]Ex(9-39) was successfully prepared and used for PET imaging for the first time to measure pancreatic BCM. The results suggest that derivatization of the Lys27 residue might reduce binding affinity, as evidenced by the absence of specific binding. Exendin analogues radiolabeled at other sites may elucidate the active site required for binding.
Authors: T D Harris; M Sworin; N Williams; M Rajopadhye; P R Damphousse; D Glowacka; M J Poirier; K Yu Journal: Bioconjug Chem Date: 1999 Sep-Oct Impact factor: 4.774
Authors: Tarun Singhal; Yu-Shin Ding; David Weinzimmer; Marc D Normandin; David Labaree; Jim Ropchan; Nabeel Nabulsi; Shu-fei Lin; Marc B Skaddan; Walter C Soeller; Yiyun Huang; Richard E Carson; Judith L Treadway; Gary W Cline Journal: Mol Imaging Biol Date: 2010-09-08 Impact factor: 3.488
Authors: Ian R Sweet; Daniel L Cook; Ake Lernmark; Carla J Greenbaum; Angela R Wallen; Erin S Marcum; Svetlana A Stekhova; Kenneth A Krohn Journal: Biochem Biophys Res Commun Date: 2004-02-20 Impact factor: 3.575
Authors: Sohee Son; Su Young Chae; Chang Wan Kim; Yang Gyu Choi; Sung Youb Jung; Seulki Lee; Kang Choon Lee Journal: J Med Chem Date: 2009-11-12 Impact factor: 7.446
Authors: Maarten Brom; Wietske Woliner-van der Weg; Lieke Joosten; Cathelijne Frielink; Thomas Bouckenooghe; Paul Rijken; Karolina Andralojc; Burkhard J Göke; Marion de Jong; Decio L Eizirik; Martin Béhé; Tony Lahoutte; Wim J G Oyen; Cees J Tack; Marcel Janssen; Otto C Boerman; Martin Gotthardt Journal: Diabetologia Date: 2014-02-01 Impact factor: 10.122
Authors: Susan M Clardy; Edmund J Keliher; James F Mohan; Matt Sebas; Christophe Benoist; Diane Mathis; Ralph Weissleder Journal: Bioconjug Chem Date: 2013-12-20 Impact factor: 4.774
Authors: Rajaa El Bekay; Leticia Coín-Aragüez; Diego Fernández-García; Wilfredo Oliva-Olivera; Rosa Bernal-López; Mercedes Clemente-Postigo; Javier Delgado-Lista; Alberto Diaz-Ruiz; Rocío Guzman-Ruiz; Rafael Vázquez-Martínez; Said Lhamyani; María Mar Roca-Rodríguez; Sonia Fernandez Veledo; Joan Vendrell; María M Malagón; Francisco José Tinahones Journal: Br J Pharmacol Date: 2016-04-28 Impact factor: 8.739